@article{300bb09d643b4d04b197157f0cd66325,
title = "A review of ocular drug delivery platforms and drugs for infectious and noninfectious uveitis: The past, present, and future",
abstract = "Uveitis refers to a broad group of inflammatory disorders of the eye that often require medical and surgical management to improve or stabilize vision and prevent vision-threatening pathological changes to the eye. Drug delivery to the eye to combat inflammation and subsequent complications from uveitic conditions is complex as there are multiple barriers to absorption limiting availability of the needed drug in the affected tissues. As such, there has been substantial interest in developing new drugs and drug delivery platforms to help reduce intraocular inflammation and its complications. In this review, we discuss the challenges of drug delivery, novel technologies recently approved for uveitis patient care and promising drug delivery platforms for uveitis and sequelae of ocular inflammation.",
keywords = "Drug delivery, Eye, Inflammation, Uveitis",
author = "Conrady, {Christopher D.} and Steven Yeh",
note = "Funding Information: Funding: This project was supported by the National Eye Institute of the National Institutes of Health under award number R01 EY029594 (Yeh) and P30-EY06360 (Department of Ophthalmology, Emory University School of Medicine). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was also supported an unrestricted departmental grant from Research to Prevent Blindness, Inc. to the Emory Eye Center, Emory University School of Medicine and the Association for Research in Vision and Ophthalmology Mallinckrodt Young Investigator{\textquoteright}s Award (Yeh). Funding Information: This project was supported by the National Eye Institute of the National Institutes of Health under award number R01 EY029594 (Yeh) and P30-EY06360 (Department of Ophthalmology, Emory University School of Medicine). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was also supported an unrestricted departmental grant from Research to Prevent Blindness, Inc. to the Emory Eye Center, Emory University School of Medicine and the Association for Research in Vision and Ophthalmology Mallinckrodt Young Investigator?s Award (Yeh). Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = aug,
doi = "10.3390/pharmaceutics13081224",
language = "English (US)",
volume = "13",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",
}